NCT01599104View on ClinicalTrials.gov

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

1,161

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Essential Hypertension
Interventions
DRUG

LCZ696

200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily

DRUG

Olmesartan

Olmesartan 20 mg capsule one daily

DRUG

Placebo

Placebo to LCZ696 or Olmesartan

Trial Locations (61)

296-8602

Novartis Investigative Site, Kamogawa

811-1244

Novartis Investigative Site, Chikushi-gun

810-0014

Novartis Investigative Site, Fukuoka

810-0066

Novartis Investigative Site, Fukuoka

812-8582

Novartis Investigative Site, Fukuoka

814-0032

Novartis Investigative Site, Fukuoka

800-0225

Novartis Investigative Site, Kitakyushu

807-0856

Novartis Investigative Site, Kitakyushu

078-8214

Novartis Investigative Site, Asahikawa

003-0026

Novartis Investigative Site, Sapporo

003-0825

Novartis Investigative Site, Sapporo

006-0811

Novartis Investigative Site, Sapporo

062-0053

Novartis Investigative Site, Sapporo

063-0842

Novartis Investigative Site, Sapporo

660-0814

Novartis Investigative Site, Amagasaki

317-0077

Novartis Investigative Site, Hitachi

210-0852

Novartis Investigative Site, Kawasaki

231-0023

Novartis Investigative Site, Yokohama

236-0004

Novartis Investigative Site, Yokohama

615-0035

Novartis Investigative Site, Kyoto

615-8125

Novartis Investigative Site, Kyoto

610-0361

Novartis Investigative Site, Kyōtanabe

634-8522

Novartis Investigative Site, Kashihara

567-0876

Novartis Investigative Site, Ibadraki

536-0008

Novartis Investigative Site, Osaka

547-0013

Novartis Investigative Site, Osaka

550-0013

Novartis Investigative Site, Osaka

560-0005

Novartis Investigative Site, Osaka

560-0082

Novartis Investigative Site, Toyonaka

362-8588

Novartis Investigative Site, Ageo

356-0053

Novartis Investigative Site, Fujimino

355-0328

Novartis Investigative Site, Hiki-Gun

343-0826

Novartis Investigative Site, Koshigaya

352-0014

Novartis Investigative Site, Niiza

337-0012

Novartis Investigative Site, Saitama

350-0202

Novartis Investigative Site, Sakado

359-1161

Novartis Investigative Site, Tokorozawa

329-0498

Novartis Investigative Site, Shimotsuke

113-0031

Novartis Investigative Site, Bunkyo-ku

113-8655

Novartis Investigative Site, Bunkyo-ku

100-0005

Novartis Investigative Site, Chiyoda-ku

133-0061

Novartis Investigative Site, Edogawa-ku

134-0084

Novartis Investigative Site, Edogawa-ku

192-0046

Novartis Investigative Site, Hachiōji

192-0918

Novartis Investigative Site, Hachiōji

124-0024

Novartis Investigative Site, Katsushika-ku

204-0021

Novartis Investigative Site, Kiyose

186-0001

Novartis Investigative Site, Kunitachi

152-0031

Novartis Investigative Site, Meguro-ku

105-7390

Novartis Investigative Site, Minato-ku

108-0075

Novartis Investigative Site, Minato-ku

177-0051

Novartis Investigative Site, Nerima-ku

143-0023

Novartis Investigative Site, Ōta-ku

150-0002

Novartis Investigative Site, Shibuya-ku

141-0032

Novartis Investigative Site, Shinagawa-ku

142-0053

Novartis Investigative Site, Shinagawa-ku

142-0063

Novartis Investigative Site, Shinagawa-ku

160-8582

Novartis Investigative Site, Shinjuku-ku

190-0013

Novartis Investigative Site, Tachikawa

111-0052

Novartis Investigative Site, Taitō City

171-0021

Novartis Investigative Site, Toshima-ku

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY